血小板相关参数评估乙型肝炎病毒相关肝细胞癌发生风险和预后的研究进展

摘要/Abstract

摘要： 乙型肝炎病毒(HBV)是全球范围内肝细胞癌的主要病因之一。乙型肝炎病毒相关肝细胞癌(HBV-HCC)的早期诊断和预后评估对于提高患者生存率和改善生活质量至关重要。血小板相关参数作为血液检验的重要部分,易于获取且成本较低,与HBV-HCC发生风险和预后密切相关。本综述旨在总结血小板相关参数在评估HBV-HCC发生风险及预后价值的研究进展,重点关注血小板计数及其相关比值指标。

关键词: 血小板相关参数, 乙型肝炎病毒, 肝细胞癌, 诊断, 预后

刘丁境, 牛日雨, 尹伟, 李成忠. 血小板相关参数评估乙型肝炎病毒相关肝细胞癌发生风险和预后的研究进展[J]. 肝脏, 2025, 30(8): 1165-1168.

/ 推荐

[1] Sung H, Ferlay J, Siegel R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021,71(3):209-249.
[2] Llovet J M, Kelley R K, Villanueva A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021,7(1):6.
[3] Burki T. WHO′s 2024 global hepatitis report[J]. Lancet Infect Dis,2024,24(6):e362-e363.
[4] Pavlovic N, Rani B, Gerwins P, et al. Platelets as key factors in hepatocellular carcinoma[J]. Cancers,2019,11(7):1022.
[5] Cuesta A M, Palao N, Bragado P, et al. New and old key players in liver cancer[J]. Int J Mol Sci,2023,24(24):17152.
[6] Zhang Q, Shi B, Wu L. Characteristics and risk factors of infections in patients with HBV-related acute-on-chronic liver failure: a retrospective study[J]. PeerJ,2022,10:e13519.
[7] Fan Z, Wu M, Tang Z, et al. Predictive value of platelet-related measures in patients with hepatocellular carcinoma[J]. Technol Cancer Res Treat,2022,21:15330338211064414.
[8] Yu J I, Park H C, Yoo G S, et al. Clinical importance of the absolute count of neutrophils, lymphocytes, monocytes, and platelets in newly diagnosed hepatocellular carcinoma[J]. Sci Rep,2021,11(1):2614.
[9] Lee H W, Park S Y, Lee M, et al. An optimized hepatocellular carcinoma prediction model for chronic hepatitis B with well-controlled viremia[J]. Liver Int,2020,40(7):1736-1743.
[10] Chun H S, Papatheodoridis G V, Lee M, et al. PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B[J]. J Hepatol,2024,80(1):20-30.
[11] Sinn D H, Kim S E, Kim B K, et al. The risk of hepatocellular carcinoma among chronic hepatitis B virus-infected patients outside current treatment criteria[J]. J Viral Hepat, 2019,26(12):1465-1472.
[12] Kim S U, Chon Y E, Seo Y S, et al. A multi-centre study of trends in hepatitis B virus-related hepatocellular carcinoma risk over time during long-term entecavir therapy[J]. J Viral Hepat,2020,27(12):1352-1358.
[13] Liu K, Huang Z, Yang S, et al. The age, gamma-glutamyl transpeptidase and platelet index: a novel noninvasive model for predicting hepatocellular carcinoma in patients with hepatitis B virus-related liver cirrhosis[J]. J Hepatocell Carcinoma,2022,9:1057-1063.
[14] Mao H, Zheng S, Yang S, et al. A new model predicts hepatocellular carcinoma in patients with HBV-related decompensated liver cirrhosis and long-term antiviral therapy: a prospective study[J]. PeerJ, 2023,11:e15014.
[15] Peng W, Li C, Zhang X, et al. The impact of thrombocytopenia on prognosis of HBV-related small hepatocellular carcinoma: a propensity score matching analysis[J]. World J Surg Oncol,2021,19(1):46.
[16] Wu C, Chau G, Lee I, et al. Early and late recurrence of surgically resected hepatitis B virus-related hepatocellular carcinoma on nucleos(t)ide analogues therapy[J]. J Formos Med Assoc,2021,120(8):1563-1571.
[17] Huang R, Zheng Y, Zou W, et al. Blood biomarkers predict survival outcomes in patients with hepatitis B virus-induced hepatocellular carcinoma treated with PD-1 inhibitors[J]. J Immunol Res,2022,2022:3781109.
[18] Yang Y, Wang M C, Tian T, et al. A high preoperative platelet-lymphocyte ratio is a negative predictor of survival after liver resection for hepatitis B virus-related hepatocellular carcinoma: a retrospective study[J]. Front Oncol,2020,10:576205.
[19] Zheng X, Ye B, Gou Y, et al. Neutrophil to lymphocyte and platelet to lymphocyte ratios as biomarkers to predict relapse and survival in posthepatectomy HBV-related hepatocellular carcinoma: a meta-analysis and preliminary immune perspective[J]. Transl Cancer Res,2021,10(3):1261-1272.
[20] Wenpei G, Yuan L, Liangbo L, et al. Predictive value of preoperative inflammatory indexes for postoperative early recurrence of hepatitis B-related hepatocellular carcinoma[J]. Front Oncol,2023,13:1142168.
[21] Yao Y, Zhang M, Liu D, et al. Changes in systemic immune-inflammation index (SII) predict the prognosis of patients with hepatitis B-related hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors[J]. Clin Transl Oncol,2025, 27(3):1155-1165.
[22] Zhang C, Wu J, Xu J, et al. Association between aspartate aminotransferase-to-platelet ratio index and hepatocellular carcinoma risk in patients with chronic hepatitis: a meta-analysis of cohort study[J]. Dis Markers,2019,2019:2046825.
[23] Lai L, Su T, Liang Z, et al. Development and assessment of novel predictive nomograms based on APRI for hepatitis B virus-associated small solitary hepatocellular carcinoma with stereotactic body radiotherapy[J]. J Cancer,2020,11(22):6642-6652.
[24] Han Y, Liu J, Pan J, et al. Prognosis and risk factors of recurrence in HBV-related small hepatocellular carcinoma after stereotactic body radiation therapy[J]. Front Oncol,2022,12:903355.
[25] Mai R Y, Wang Y Y, Bai T, et al. Combination of AlbI and APRI to predict post-hepatectomy liver failure after liver resection for HBV-related HCC patients[J]. Cancer Manag Res,2019,11:8799-8806.
[26] Dai T, Deng M, Ye L, et al. Prognostic value of combined preoperative gamma-glutamyl transpeptidase to platelet ratio and fibrinogen in patients with HBV-related hepatocellular carcinoma after hepatectomy[J]. Am J Transl Res,2020,12(6):2984-2997.
[27] 梅宝富, 邓志锋, 郑兰, 等. γ-谷氨酰转肽酶和血小板比值对肝癌介入术后急性肝功能恶化的预测作用[J]. 肝脏, 2021,26(2):175-178.
[28] Seong G, Sinn D H, Kang W, et al. Age and fibrosis index for the prediction of hepatocellular carcinoma risk in patients with high hepatitis B virus DNA but normal alanine aminotransferase[J]. Eur J Gastroenterol Hepatol,2022,34(1):69-75.
[29] Tseng T C, Choi J, Nguyen M H, et al. One-year fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment[J]. Hepatol Int,2021,15(1):105-113.
[30] Kuwano A, Miyazaki M, Yada M, et al. FIB-4 index and serum alpha-fetoprotein are useful predictors of hepatocellular carcinoma occurrence in hepatitis B patients with nucleos(t)ide analogs therapy[J]. Exp Ther Med,2023,26(3):441.
[31] Luo J, Yuan M, Li S, et al. Dynamic evaluation of liver fibrosis to assess hepatocellular carcinoma risk in patients with chronic hepatitis B receiving nucleoside analogs treatment[J]. Rev Inst Med Trop Sao Paulo,2024,66:e27.
[32] Tsai M Y, Yen Y H, Huang P Y, et al. The pre- and postoperative FIB-4 indexes are good predictors to the outcomes of HBV-related HCC patients after resection[J]. Gastroenterol Res Pract,2019,2019:8945798.
[33] Gao T M, Jin S J, Fang F, et al. Novel preoperative type IV collagen to predict the risk of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhotic portal hypertension after laparoscopic splenectomy and azygoportal disconnection[J]. J Hepatocell Carcinoma,2023,10:2411-2420.

血小板相关参数评估乙型肝炎病毒相关肝细胞癌发生风险和预后的研究进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨啸天, 张颖, 郑昕. 乙型肝炎病毒相关肝细胞癌复发的空间——免疫研究进展[J]. 肝脏, 2025, 30(8): 1023-1025.
[2]	周靖媛, 周嘉, 柳涛, 高沿航. 酒精性肝病相关肝细胞癌与其他病因所致肝细胞癌的差异[J]. 肝脏, 2025, 30(8): 1028-1032.
[3]	朱碧莲, 唐映梅, 包维民, 李秦念. 急性戊型肝炎临床特征及进展为肝衰竭的危险因素分析[J]. 肝脏, 2025, 30(8): 1039-1045.
[4]	王杏珍, 刘开颜, 王晓燕. 妊娠期乙型肝炎病毒感染患者孕期药物干预策略对母婴预后及产后肝炎发作的影响[J]. 肝脏, 2025, 30(8): 1046-1050.
[5]	马肖敏, 蒋叶舟, 陈国飞. 血清胰岛素样生长因子结合蛋白-7水平对乙型肝炎肝硬化并发急性肾损伤患者的诊断价值[J]. 肝脏, 2025, 30(8): 1061-1065.
[6]	朱冉, 陈淑娆, 邹梦琦, 杨宇峰. 早发性肝细胞癌与非早发性肝细胞癌的临床病理特征比较[J]. 肝脏, 2025, 30(8): 1093-1096.
[7]	黎星, 杨进, 卢森, 邓国林, 陈娅. 脓毒症继发急性肝衰竭患者生存预后状况及其风险因素分析[J]. 肝脏, 2025, 30(8): 1124-1128.
[8]	姜慧杰, 蒋雪梅. 慢加急性肝衰竭预后评分系统的研究进展姜慧杰蒋雪梅[J]. 肝脏, 2025, 30(8): 1160-1165.
[9]	梁群, 付伟. 艾米替诺福韦治疗乙型肝炎肝硬化伴低病毒血症2例及文献复习[J]. 肝脏, 2025, 30(8): 1169-1170.
[10]	蒋素贞, 王竞州, 陈香梅, 鲁凤民. 宿主HBV特异性细胞免疫或是慢性乙型肝炎患者核苷(酸)类药物停药不复发和HBsAg清除的决定因素[J]. 肝脏, 2025, 30(7): 889-892.
[11]	李玉龙, 张欣欣. HBsAg亚病毒颗粒:miRNA递送载体及潜在治疗应用[J]. 肝脏, 2025, 30(7): 897-900.
[12]	李卉, 周义文, 王务军, 陈江波. 微波消融联合信迪利单抗对中晚期肝细胞癌患者疾病控制效果、免疫功能及预后的影响[J]. 肝脏, 2025, 30(7): 934-937.
[13]	李晓艳, 张景芳, 王春萍, 周平安. 超声造影联合CT定量参数鉴别诊断肝脏局灶性结节增生与肝细胞癌的价值研究[J]. 肝脏, 2025, 30(7): 938-942.
[14]	杨斌, 王勇刚, 曹洪刚, 高建勇. HBV相关肝细胞癌患者血清UCA1、WRAP53表达水平及其临床意义[J]. 肝脏, 2025, 30(7): 943-947.
[15]	李龙, 郑振东, 杜成, 刘渤娜. HCC患者接受营养干预后BMI、PNI、NPAR水平变化及其对生存质量的影响[J]. 肝脏, 2025, 30(7): 948-952.